Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLA-SE · 1 trial · 1 indication
The number of treatment-related adverse events
| Arm | Type | Description |
|---|---|---|
| GLA-SE | EXPERIMENTAL | Glucopyranosyl Lipid A in Stable Emulsion |
| Name | Type | Description |
|---|---|---|
| GLA-SE | BIOLOGICAL | Glucopyranosyl Lipid A in Stable Emulsion |
Inclusion Criteria: * Biopsy-confirmed Merkel cell carcinoma with metastatic or loco-regional disease. * Patients must have at least one injectable lesion, defined as an easily palpable superficial lesion (cutaneous, subcutaneous or lymph nodal metastasis) that can be accurately localized, stabiliz...
GLA-SE is an investigational monoclonal antibody being studied for the treatment of Merkel Cell Carcinoma. It is currently in Phase 1 clinical development, with one completed proof-of-concept trial involving 10 patients in the United States.
GLA-SE is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential role in treating Merkel Cell Carcinoma, a type of skin cancer.
GLA-SE is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DSGN. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Merkel Cell Carcinoma.
GLA-SE is in Phase 1 clinical development. A proof-of-concept trial (NCT02035657) has been completed, enrolling 10 patients with Merkel Cell Carcinoma. The drug is investigational and has not been approved by regulatory authorities.
GLA-SE has one completed clinical trial, NCT02035657, titled "A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma." This Phase 1 study enrolled 10 adult patients in the United States and was not randomized or blinded.